Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $29.59, for a total value of $5,918,000.00. Following the transaction, the chief executive officer owned 1,647,546 shares of the company’s stock, valued at approximately $48,750,886.14. The trade was a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $28.24, for a total transaction of $5,648,000.00.
• On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $28.14 on Friday. The company’s 50-day moving average price is $28.22 and its two-hundred day moving average price is $23.50. Roivant Sciences Ltd. has a one year low of $10.58 and a one year high of $30.33. The stock has a market capitalization of $20.14 billion, a PE ratio of -24.05 and a beta of 1.20.

Institutional Trading of Roivant Sciences

A number of hedge funds have recently made changes to their positions in ROIV. UBS Group AG lifted its position in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the last quarter. Morgan Stanley lifted its position in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Roivant Sciences by 11,507.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after buying an additional 6,877,348 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $112,750,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ROIV shares. Sanford C. Bernstein started coverage on Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. HC Wainwright upped their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Weiss Ratings cut Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. Finally, Citigroup upped their price objective on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.55.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.